Tasly Pharmaceutical to Start Phase III Trial of TCM Angina Treatment in US
8/9/2010 11:57:45 AM
August 9, 2010 -- Tianjin Tasly Pharmaceutical said its patented TCM treatment for angina, Compound Danshen Dripping Pills, posted positive results in a Phase II trial conducted in the US. The FDA has also given its go-ahead to move the drug into Phase III trials, according to Tasly. Assuming a positive outcome for the trial, the company hopes to launch the drug in the US as early as 2013. Tasly said Danshen is the first TCM drug approved by the FDA for Phase III trials. More details....